First-in-Human – Treatment of Merkel Cell Carcinoma.
Phase 1 clinical study evaluating ITI-3000 in patients with Merkel cell carcinoma.
Phase 1 clinical study evaluating ITI-3000 in patients with Merkel cell carcinoma.
The company anticipates reporting top-line results in the second quarter of this year.
Reviva anticipates expanding the clinical development of brilaroxazine into other neuropsychiatric indications.
The vaccine was designed to prompt white blood cells turn into antibodies that could neutralize HIV.
The multicentre, randomized trial of L1-79 will enroll nearly 50 subjects of the age 12 to 21 years.
Screening for eligible subjects for the trial has started and enrollment is anticipated to conclude in nearly one year.
OUTREACH-2 study evaluating MTL-CEBPA in combination with sorafenib in up to 150 patients.
Ensifentrine is a first-in-class product candidate that combines bronchodilator and anti-inflammatory activities in one compound.
The trial is expected to enrol subjects across 100 sites in North America, Asia Pacific and Europe.
In preclinical studies, NE3107 was shown to improve motor symptoms as effectively as L-dopa.